The strong beat and raised guidance confirm accelerating momentum in HVP Components and Biologics, with GLP-1 elastomers contributing 10% of revenue. Watch for continued margin expansion as HVP mix improves and the SmartDose divestiture closes mid-year. The Q3 guidance implies a sequential revenue dip due to SmartDose removal, but organic growth remains robust at 7-9%.
Price Chart
Executive Summary
West Pharmaceutical Services reported Q2 2026 results that significantly exceeded consensus expectations, with adjusted diluted EPS of $2.37 beating the $2.08 estimate by 13.9% and revenue of $872.3M beating the $840.0M estimate by 3.8%. The company raised its full-year 2026 adjusted EPS guidance to $8.85-$9.05 (from $8.40-$8.75) and net sales guidance to $3.345B-$3.380B, driven by strong organic growth of 12.7% led by High-Value Product Components and Biologics demand.
Key Financial Metrics
Key Facts
- Q2 2026 net sales $872.3M, +13.8% reported, +12.7% organic YoY
- Adjusted diluted EPS $2.37, +28.8% YoY, beating consensus of $2.08 by 13.9%
- GAAP diluted EPS $2.15, +18.1% YoY
- Full-year 2026 adjusted EPS guidance raised to $8.85-$9.05 from $8.40-$8.75
- Full-year 2026 net sales guidance raised to $3.345B-$3.380B from $3.295B-$3.350B
- Q3 2026 guidance: net sales $820M-$835M, adjusted EPS $2.14-$2.24
- H1 2026 operating cash flow $213.9M, free cash flow $128.0M
- Proprietary Products segment net sales $722.6M, +16.6% reported, +15.5% organic
- HVP Components net sales $424.1M, +19.4% reported, +18.4% organic, 49% of total sales
- Biologics market group grew 30.3% reported, 29.2% organic
- West Vantage segment net sales $149.7M, +2.0% reported, +0.8% organic; margins compressed due to cyber incident
- Share repurchases of 1.8M shares for $454.3M in H1 2026 at avg $258.03/share
- Dividend of $0.22 per share declared for Q3 2026
Financial Impact
Adjusted EPS beat consensus by $0.29 (13.9%), revenue beat by $32.3M (3.8%). Full-year guidance raised by $0.45 at midpoint for adjusted EPS and $40M at midpoint for net sales.
Risk Factors
- West Vantage segment margin compression due to May 2026 cybersecurity incident
- Currency headwinds: ~1pp headwind on Q3 revenue guidance
- SmartDose 3.5mL divestiture to AbbVie removes ~$55M in H2 2025 revenue, creating a reported growth drag in Q3
- Cost-method investment impairment of $3.5M in Q2
- Potential for slower GLP-1 elastomer growth if drug demand softens
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000105770-26-000097 |
| Document: wst-20260723.htm | 0000105770-26-000097 |
| Document: a2q26earningsdeck-final.htm | 0000105770-26-000097 |
| Document: 0000105770-26-000097-index-headers.html | 0000105770-26-000097 |
| Document: 0000105770-26-000097-index.html | 0000105770-26-000097 |
| Document: 0000105770-26-000097.txt | 0000105770-26-000097 |
| 8-K Data (Synthetic) | 0000105770-26-000097 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 23, 2026 10w ago | 8-K | $355.48 $353.77 | ▼ −0.48% | ▼ −3.79% | $364.89 (+2.65%) |
Jul 23, 2026 10w ago | Press Release | $355.48 $353.77 | ▼ −0.48% | ▼ −3.79% | $364.89 (+2.65%) |
Jul 7, 2026 12w ago | Press Release | $356.08 $347.94 | ▼ −2.29% | ▼ −3.62% | $364.89 (+2.47%) |
May 11, 2026 20w ago | 8-K | $311.82 $330.92 | ▼ −6.12% | ▼ −7.85% | $364.89 (−17.02%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
Apr 27, 2026 22w ago | Insider Cluster | $300.93 $316.17 | ▲ +5.06% | ▲ +0.11% | $364.89 (+21.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access